Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices used across a wide range of interventional specialties. The company’s portfolio is built around less-invasive therapies that help physicians diagnose and treat disease while reducing the need for traditional surgery. Its products are sold globally to hospitals, clinics, outpatient facilities, and physician offices, with a large share of sales influenced by hospital purchasing groups and reimbursement dynamics. Over more than 45 years in medical technology, Boston Scientific has built a business centered on continuous product innovation, clinical evidence, and broad commercial reach.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevices used in interventional cardiology, electrophysiology, and peripheral vascular procedures.
Tools and systems used to diagnose and treat gastrointestinal and other conditions through minimally invasive procedures.
Products for urinary tract, kidney stone, and pelvic floor-related procedures and therapies.
Implantable and related therapies used to manage chronic pain and other neurological conditions.
Therapies and devices for cancer treatment, including liver cancer and embolization procedures.
Products
Reported · share of revenue- Interventional Cardiology Vascular Therapies23.1 %
- Electrophysiology EP16.6 %
- Global Endoscopy Endo Reporting Unit14.5 %
- Global Urologyand Pelvic Health Reporting Unit13.5 %
- Cardiac Rhythm Management11.6 %
- Other20.8 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Boston Scientific sells primarily to healthcare providers that perform interventional procedures, including hospitals, clinics, outpatient facilities, ambulatory surgery centers, and medical offices. Physicians and hospital service-line administrators are key decision-makers because the company’s products are used in procedure-based care where clinical outcomes, ease of use, and reimbursement matter. Large group purchasing organizations, hospital networks, and other buying groups are important because they influence pricing, contracting, and access across consolidated health systems. The company also relies on distributors in some countries, but most net sales come from direct sales organizations in markets where it has a commercial presence. Demand is tied to procedure volumes, site-of-care shifts, and the willingness of payers to reimburse less-invasive treatments.
Buy the core interventional device portfolio for procedure rooms and specialty departments because they need reliable clinical outcomes and broad product availability.
Influence product choice in cardiology, endoscopy, urology, and oncology based on ease of use, efficacy, and training support.
Purchase devices for procedures migrating out of inpatient settings, where efficiency and reimbursement economics are critical.
Negotiate contracts and pricing across consolidated provider systems, affecting access and average selling prices.
Buy and resell products in selected markets where Boston Scientific does not maintain a direct commercial footprint.
Strategy
Boston Scientific’s strategy is centered on five stated imperatives: strengthen category leadership, expand into high-growth adjacencies, drive global expansion, fund the journey to fuel growth, and develop key capabilities. This points to a portfolio strategy that combines defending core franchises with adding adjacent technologies that can be sold through the same clinical and hospital channels. The company also emphasizes innovation, clinical trials, and timely regulatory approvals as the path to launching next-generation products. Commercially, it seeks to leverage direct sales infrastructure in major markets while using distributors where that is more efficient. The strategy is designed to support profitable revenue growth in a highly competitive and regulated device market.
Core franchises provide the scale, clinical credibility, and commercial leverage that support repeat purchasing and hospital access.
Adjacent categories can reuse the company’s sales channels and clinical relationships while broadening growth beyond mature lines.
International markets increase the addressable customer base and reduce dependence on any single healthcare system.
Digital, regulatory, and operational capabilities are increasingly important in a device market shaped by AI, cybersecurity, and evidence requirements.
Geography
Boston Scientific is a global business with products marketed in 127 countries. The company says the majority of net sales come from countries where it maintains direct sales organizations, while distributors are used in selected markets. The United States is the most important market, but international exposure is meaningful and creates sensitivity to reimbursement policy, tendering, and local competition. China is a notable competitive risk because domestic suppliers can benefit from local-supplier advantages and pricing pressure. The company’s global footprint also means it faces foreign exchange, regulatory, and geopolitical risks across multiple healthcare systems.
Risks
Boston Scientific faces intense competition across its product lines, including pressure from large diversified device makers, niche specialists, and low-cost local competitors. Because its products are sold into procedure-based care, demand depends on procedure volumes, site-of-care shifts, reimbursement, and the purchasing power of consolidated health systems. The company also faces material regulatory, litigation, and product liability exposure, which can create legal provisions, management distraction, and cash flow volatility. Cybersecurity and IT/OT disruption are important operational risks because the company relies on global systems to manufacture, ship, and protect sensitive patient and product data. More broadly, medical device companies face risks from slower approvals, failed clinical trials, pricing pressure, and changing healthcare policy in the U.S., EU, and other markets.
- Competitive pricing pressure and market share lossImpact: HighLikelihood: High
The company competes against large diversified device makers, niche specialists, and low-cost entrants, which can force concessions and reduce average selling prices.
Exposure: Core interventional device franchises
- Regulatory and reimbursement changesImpact: HighLikelihood: High
Approval pathways and payer coverage determine whether new devices can launch and how quickly procedures are adopted.
Exposure - Litigation and product liabilityImpact: HighLikelihood: High
Medical device companies face claims tied to product performance, compliance, and patient outcomes, which can create legal costs and provisions.
Exposure: Global operations and legacy product lines
- Cybersecurity and IT/OT disruptionImpact: HighLikelihood: Medium
Manufacturing, shipping, and sensitive data systems depend on secure global infrastructure that can be targeted by malicious actors.
Exposure: Enterprise systems and connected operations
- China and local-supplier competitionImpact: MediumLikelihood: Medium
Domestic competitors in China may benefit from local procurement preferences and pricing advantages.
Exposure: International sales in China
Accounting
Judgemental itemsHospital contracting, rebates, and shipment timing can shift revenue between periods and affect reported growth.
Impact: Quarterly comparability and reported net sales
Acquisition-heavy growth creates large intangible balances that must be tested for impairment if performance weakens.
Impact: Potential non-cash charges to earnings
Litigation, investigations, and product claims require judgmental reserves that can change with case developments.
Impact: Earnings volatility and cash outflows
Device portfolios can face obsolescence, launch transitions, and demand changes that require write-downs.
Impact: Gross margin and operating profit
Management excludes amortization, restructuring, litigation, and acquisition-related items, which can materially change the view of underlying performance.
Impact: Adjusted earnings versus GAAP earnings
Similar listed companies
Publicly listed companies with a comparable business focus.
Baxter International Inc
BAX · Surgical & Medical Instruments & Apparatus
Penumbra Inc
PEN · Surgical & Medical Instruments & Apparatus
Penumbra is a U.S.-based medical device company focused on thrombectomy and related interventional therapies for removing blood clots from the body.
Becton, Dickinson and Company
BDX · Surgical & Medical Instruments & Apparatus
Becton, Dickinson and Company (BD) is a U.S.-based medical technology company with roots dating back to 1897 and incorporation in 1906.
Stryker Corporation
SYK · Surgical & Medical Instruments & Apparatus
Merit Medical Systems, Inc
MMSI · Surgical & Medical Instruments & Apparatus
Merit Medical Systems designs, manufactures, and markets proprietary medical devices used in interventional, diagnostic, and therapeutic procedures.
Bristol-Myers Squibb Company
BMY · Pharmaceutical Preparations
Bristol Myers Squibb is a U.S.-based biopharmaceutical company that discovers, develops, manufactures, markets, and sells innovative medicines for serious diseases.
Last updated: 24/09/2026